Moleculin Biotech, Inc. — Form SCHEDULE 13D
Filed August 25, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 42/100
What the filing says
ANNAMED, Inc., by Walter V. Klemp (Chairman and CEO), filed a joint Schedule 13D on August 25, 2026, regarding a position in Moleculin Biotech. The filing document provided is the joint filing agreement only; the actual Schedule 13D detailing stake size, acquisition details, and intent is not included in this excerpt. No specific share count, percentage ownership, or dollar amount is disclosed in the text provided.
Why this rating
Schedule 13D filing indicates material stake (typically ≥5%), but core details absent. Relative to $8.8M market cap, even modest stake could matter; disclosure intent unclear from agreement alone.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.